DO-2 is a best-in-class MET kinase inhibitor that has completed enrollment in a Phase 1 dose escalation study Tumor shrinkage was observed in 100% of MET exon 14 skip NSCLC patients without additional oncogenic drivers, at doses that achieved preclinically defined thresholds DO-2 has a very good safety profile with minimal peripheral oedema and clean […]
Resolution leadership team joined by world leading clinical hepatologist Elliot Tapper, MD, FAASLD, and EMERALD Chief Investigator Professor Jonathan Fallowfield Edinburgh and London, UK, 27 August 2025 – Resolution Therapeutics (“Resolution” or “Company”), a clinical-stage biopharmaceutical company pioneering regenerative macrophage therapies to treat inflammatory and fibrotic diseases, today announces that it will host a virtual […]
Orally administered treatment was well tolerated, with early signs of clinical activity In models of non-proliferative diabetic retinopathy (NPDR), danegaptide has demonstrated protection against retinal capillary loss and vascular leakage Data support continued advancement into Phase 2 clinical evaluation Copenhagen, Denmark, 24 June 2025 – Breye Therapeutics ApS (Breye), a clinical-stage ophthalmology focused biopharmaceutical company […]
ALY-301 is a first-in-class bispecific antibody targeting c-Kit and CD-203c with mast cell selectivity Designed to enable safe dosing in chronic conditions and deliver clinical proof-of concept in a Phase 1/1b study Boston, Massachusetts and Lausanne, Switzerland, 10 June 2025 – Alys Pharmaceuticals, Inc. (“Alys”), an immune-dermatology focused company, today announces the submission of a […]
Strategic agreement secures access to essential oncology injectables for clinical trials as European shortages intensify LONDON, UK – 29 May 2025: Bionical Emas, a global provider of Clinical Trial Services, announces an exclusive global clinical trial supply agreement with Pharma Resources GmbH, German pharmaceutical company and marketing authorization holder, specialized in oncology. This strategic partnership […]
